Amedisys - AMED Stock Forecast, Price & News

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Amedisys Price Performance

Shares of AMED opened at $119.43 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.92 and a quick ratio of 0.92. The company has a market cap of $3.87 billion, a P/E ratio of 27.84, a PEG ratio of 2.97 and a beta of 0.95. Amedisys has a 12 month low of $101.61 and a 12 month high of $188.88. The stock has a fifty day moving average price of $119.33 and a 200 day moving average price of $134.06.

Amedisys (NASDAQ:AMED - Get Rating) last released its quarterly earnings results on Wednesday, July 27th. The health services provider reported $1.47 EPS for the quarter, topping the consensus estimate of $1.23 by $0.24. The business had revenue of $557.89 million during the quarter, compared to analyst estimates of $583.12 million. Amedisys had a net margin of 6.33% and a return on equity of 17.81%. The company's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.69 earnings per share. On average, research analysts forecast that Amedisys will post 5.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMED. Oppenheimer dropped their target price on Amedisys from $200.00 to $175.00 in a research report on Friday, July 29th. SVB Leerink cut their target price on Amedisys from $117.00 to $107.00 and set a "market perform" rating on the stock in a research report on Tuesday, June 21st. Jefferies Financial Group reissued a "buy" rating and set a $200.00 price target on shares of Amedisys in a research report on Tuesday, June 28th. Stifel Nicolaus started coverage on shares of Amedisys in a report on Tuesday, June 28th. They issued a "hold" rating and a $128.00 price target on the stock. Finally, Bank of America downgraded shares of Amedisys from a "neutral" rating to an "underperform" rating and reduced their price objective for the company from $145.00 to $102.00 in a research note on Tuesday, June 21st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Amedisys presently has an average rating of "Hold" and a consensus target price of $158.53.

Insider Buying and Selling at Amedisys

In other news, insider Denise M. Bohnert sold 557 shares of the business's stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total transaction of $64,055.00. Following the completion of the transaction, the insider now directly owns 11,850 shares in the company, valued at $1,362,750. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.10% of the stock is owned by company insiders.